WASHINGTON, March 13, 2009 (GLOBE NEWSWIRE) -- Finkelstein Thompson LLP is currently investigating possible shareholder claims arising from potential breaches of fiduciary duty by certain executives and directors of Life Sciences Research, Inc. (NYSE:LSR) in connection with the proposal by Andrew Baker, LSR's Chairman and Chief Executive Officer, to acquire all of the outstanding shares of LSR for a price of $7.50 per share pursuant to a letter dated March 3, 2009. The investigation is focused on the possible inadequacy of the consideration to be paid to the public shareholders as well as the potential unfairness of the procedures followed by the Board in connection with this proposal.
If you are interested in discussing your rights as an LSR shareholder, or have information relating to this investigation, please contact Finkelstein Thompson's Washington, DC offices at (877) 337-1050 or by email at contact@finkelsteinthompson.com. Finkelstein Thompson LLP has spent over three decades delivering outstanding representation to institutional and individual clients in connection with securities and other finance-related litigation, and has been appointed as lead or co-lead counsel in dozens of shareholder class actions. Indeed, the firm has served in leadership roles in cases that have recovered over $1 billion for investors and consumers.
To learn more about Finkelstein Thompson LLP, please visit our web site at www.finkelsteinthompson.com.